# Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant

> **NCT00002790** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Fred Hutchinson Cancer Center**

## Conditions studied

- Graft Versus Host Disease
- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** cyclosporine
- **DRUG:** methotrexate
- **DRUG:** sirolimus

## Key facts

- **NCT ID:** NCT00002790
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1996-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002790, "Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00002790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*